Slide 1: OTX-TKI U.S.-based Wet AMD Clinical Trial Design
Month 10 Analysis (Presented at Angiogenesis 2023) Month 7 Analysis (Presented at AAO 2022) 1 OTX - TKI U.S. - based Wet AMD Clinical Trial Design OTX - TKI Arm Aflibercept Arm OTX - TKI 600µg single implant injection Aflibercept 2mg injection Sham injection Study Visit Multicenter, Randomized, Doub
Slide 2: Baseline Characteristics
2 Baseline Characteristics Baseline Characteristic OTX - TKI (N=16) † Aflibercept (N=5) Mean (SD) Age, Years 76 (8) 84 (8) Male, n (%) Female, n (%) 8 (50) 8 (50) 3 (60) 2 (40) Mean (SD) Months since wet AMD diagnosis 18 (12) 18 (12) Mean (SD) Number of anti - VEGF Injections within 12 Months Prior
Slide 3: Reduction in Anti-VEGF Injections Following OTX-TKI at 12 Months
-52 -48 -44 -40 -36 -32 -28 -24 -20 -16 -12 -8 -4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 Weeks OTX - TKI (n=15) Aflibercept (n=5) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Reduction in Anti - VEGF Injections Following OTX - TKI at 12 Months 89% reduction in treatment burden with OTX - TKI a
Slide 4: Demonstrated Extended Duration of Action
100% 100% 93% 93% 80% 73% 73% 73% 73% 67% 67% 60% 0% 20% 40% 60% 80% 100% Percentage of OTX - TKI Subjects Rescue - Free Up to Each Visit (n=15) 4 OTX - TKI Demonstrated Extended Duration of Action 60% were rescue - free up to 12 months with 4 additional subjects rescued at 12 months Data cut off Ap
Slide 5: Vision and CSFT with OTX-TKI were Comparable to Aflibercept Q8W
5 Vision and CSFT with OTX - TKI were Comparable to Aflibercept Q8W -70 -50 -30 -10 10 30 50 70 BL W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52 Mean CSFT Change from Baseline, µm Mean Change in CSFT -15 -10 -5 0 5 10 15 BL W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52 Mean BCVA Change from
Slide 6: Safety Summary
6 Safety Summary OTX - TKI n=16 Aflibercept n=5 Subjects with Adverse Events in the Study Eye, n (%) Elevated IOP 2 (12.5) 1 (20.0)** Retinal detachment 0 0 Retinal vasculitis 0 0 Implant migration into the anterior chamber 0 NA Acute endophthalmitis 1 (6.25)* 0 Subjects with Ocular Adverse Events i